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INTRODUCTION
HLH is a severe inflammatory syndrome characterized by
primary or secondary immune dysregulation causing
excess activation of macrophages and cytotoxic
lymphocytes, leading to multi-system dysfunction.
Diagnosing and managing HLH can be challenging for
clinicians, with HLH-2004 criteria for diagnosis requiring a
molecular diagnosis or the presence of at least five of the
following: fever, splenomegaly, cytopenia involving two
or more cell lineages, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis in the bone marrow,
spleen or lymph nodes with no evidence of malignancy,
low or no NK cell activity, elevated ferritin, or elevated
soluble IL-2 receptor1 . These criteria have been utilized to
develop the HScore, a tool used to assist in determining
the probability of HLH based on the aforementioned
abnormalities 2 . After diagnosis, treatment typically
includes chemotherapy and immunosuppression,
followed by allogeneic bone marrow transplant3 .

CASE PRESENTATION
A 27-year-old Vietnamese female with no past medical or
family history presented to the emergency department
with three weeks of intermittent fevers, headache, and
unilateral neck swelling. She immigrated to the United
States from Vietnam five years prior. She denied any
recent travel, environmental exposures, sick contacts, or
chronic medications. She denied shortness of breath,
cough, nausea, vomiting, or diarrhea.
On examination, temperature was 39.2°C, heart rate 110
beats per minute, blood pressure 112/74 mmHg,
respiratory rate 16 breaths per minute, and oxygen
saturation 96% on room air. Scleral icterus was absent.
She was tachycardic with regular cardiac rhythm, and
lungs were clear to auscultation bilaterally. Two mobile,
non-tender, left-sided cervical lymph nodes measuring
1-2cm each were palpated without further lymphadenopathy. Her abdomen was non-tender, non-distended,
and normoactive. Her skin was dry, without rashes,
petechiae, or ecchymoses.

Initial laboratory workup was notable for a hemoglobin
of 8.4 g/dL, white blood cell count of 2.9 B/L with normal
differential, aspartate aminotransferase (AST) of 308 IU/L,
and alanine aminotransferase (ALT) of 248 IU/L. Chest
radiography was negative for any acute process.
Computed tomography of the neck, chest, abdomen,
and pelvis noted trace pleural effusions, abdominopelvic
ascites, hepatosplenomegaly, and diffuse colitis. Blood
and urine cultures (including acid fast and fungal cultures)
showed no growth.
A comprehensive infectious, hematologic, and
rheumatologic workup was performed, including
mycobacterial, fungal, malarial, and zoonotic testing;
invasive studies included lumbar puncture, paracentesis,
cervical excisional lymph node biopsy, liver biopsy, and
laparoscopy with mesenteric and lymph node biopsy.
There was no evidence of active acute infection,
malignancy, or autoimmune disease on serologic testing.
Liver biopsy showed chronic hepatitis with minimal-mild
activity and no fibrosis. Peritoneal fluid showed reactive
mesothelial cells without evidence of malignancy, and
fluid cultures were negative. Mesenteric and lymph node
biopsy showed benign lymph nodes with reactive sinus
histiocytosis and focal necrosis; acid fast and fungal
stains were negative. Bone marrow biopsy and peripheral
flow cytometry revealed a hypercellular bone marrow
with trilineage hematopoiesis, occasional hemophagocytosis, adequate iron, and no evidence of leukemia/
lymphoma. Findings were discussed with hematopathology and medical oncology services, and ultimately
felt to be inconclusive. She was discharged home with
ongoing fevers but clinically stable, with plans for
outpatient follow-up.
Four months after discharge, she presented again with
nausea, vomiting, and fever. She reported returning to
Vietnam and being hospitalized there with similar but
worsening symptoms. A diagnostic workup from that
hospitalization, including bone marrow biopsy, was
unrevealing. She reported generalized myalgias, epistaxis,
malaise, and abdominal pain. On exam, temperature was
40.6°C, heart rate 105 beats per minute, blood pressure
90/64 mmHg, respiratory rate of 25 breaths per minute,

The Medicine Forum, Volume 22 | 29 5

and oxygen saturation 95% on room air. Physical exam
noted scleral icterus. She had sinus tachycardia, and lungs
were clear to auscultation bilaterally. Her abdomen was
diffusely tender to palpation with guarding, and her liver
edge was palpable. Ecchymoses were present diffusely,
and crusted blood was visualized in the nares. Labs were
notable for Hgb 8.6 g/dL, WBC 6.8 B/L with 86% neutrophils,
platelets 35 B/L, AST 3200 IU/L, AST 680 IU/L, triglycerides
273 mg/dL, ferritin 75910 ng/dL, fibrinogen 40 mg/dL, and
IL-2R of 30470 pg/mL; total HScore was 299. After receiving
steroids, intravenous fluids, and broad-spectrum
antibiotics, she was admitted to the medical intensive
care unit and initiated on dexamethasone and etoposide
per the HLH-94 protocol with improvement in her clinical
condition. She was discharged home two weeks later,
successfully completing a taper of dexamethasone and
weekly etoposide infusions with her oncologist.
Approximately eight months after discharge, she was seen
by Dermatology for erythematous firm plaques with
ulceration on her thigh that persisted for several months
despite oral antibiotics. She underwent punch biopsy of
the lesion twice; her first biopsy was inconclusive, and
second biopsy demonstrated subcutaneous panniculitislike T-cell lymphoma (SPTCL) with immunohistochemistry
showing the beta T-cell phenotype.

DISCUSSION
The non-specific components of the HLH-2004 criteria,
combined with an often-severe clinical presentation,
create a unique challenge for clinicians to differentiate
HLH from other critical illnesses; for example, data on
malignancy-associated HLH suggests that less than 50%
of patients promptly received HLH-directed therapy due
to diagnostic difficulty4. As such, early recognition of HLH
is critical. With increasing recognition and diagnosis of
adult HLH, there is greater understanding of disease
characteristics and how varying etiologies influence
patient outcomes5,6 . Although adult treatment protocols
are derived predominantly from pediatric data, new
clinical trials have the potential to change future
management of adult HLH, with drugs targeting INF-γ,
CD-52, IL-1, and JAK-STAT in varying stages of testing3,4.
In adult patients with newly diagnosed HLH, secondary
HLH remains significantly more common than primary
HLH5. While the most common etiology varies geographically, lymphoma represents the most common
malignancy-related cause and overall secondary cause of
HLH4,5 . Since its initial description, SPTCL has been closely
linked to hemophagocytic syndromes7. Representing
approximately 1% of non-Hodgkin’s lymphomas, it is
highly associated with a rapidly progressive course of
HLH8 . Flow cytometry differentiates the α/β (SPTCL-AB) or
γ/δ (SPTCL-GD) T-cell phenotypes, with SPTCL-AB usually
following a more indolent course and conferring a better
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prognosis 8 . Treatment of SPTCL is variable but often
includes steroids, other immunosuppressive agents, or
cytotoxic chemotherapy8,9.
A final diagnostic challenge was her clinical stability
without disease progression over several months; findings
such as colitis and regional lymphadenopathy initially
suggested other causes. Despite her high HScore, it was
challenging to definitively rule out infectious causes and
commit her to cytotoxic therapy. Similar diagnostic
dilemmas are likely responsible for the delayed diagnosis
and treatment widely noted in other studies. As such,
practitioners should have high clinical suspicion for
secondary HLH in adult patients with appropriate disease
markers and strongly consider workup for underlying
malignancy.

CONCLUSION
As evidenced in this case, HLH is an uncommon syndrome
that can be challenging to differentiate from other
conditions causing multi-organ system dysfunction.
Secondary HLH is significantly more common than
primary HLH in adult patients, and malignancy (especially
lymphoma) is the most common secondary etiology.
Due to the non-specific diagnostic criteria for HLH and
intense cytotoxic therapy, many patients experience
delays in diagnosis and treatment.
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